Ingredion Incorporated has announced that three of the Company’s fibers have been identified as meeting the new U.S. Food and Drug Administration (FDA) regulatory definition of “dietary fiber” for nutrition facts labels. The FDA provided guidance for eight additional isolated or synthetic non-digestible carbohydrates as dietary fibers under the proposed additions to the regulatory definition (21 CRF 101.9(c)(6)(i)). Ingredion ingredients among the updated dietary fiber list include:

• NUTRAFLORA short-chain fructooligosaccharide (scFOS) —  inulin-type fructan
• HI-MAIZE 260 high-amylose maize —  resistant starch 2
• BIOLIGO GL 5700 GOS — Galactooligosaccharide

Further information can be found on the FDA website.

“Ingredion’s fibers help to enable diverse benefits and are suitable for applications ranging from beverages to dairy to bakery to snacks,” said Maria Stewart, PhD, director of global nutrition R&D at Ingredion Incorporated. “NUTRAFLORA short-chain fructooligosaccharide, HI-MAIZE 260 resistant starch and BIOLIGO LG 5700 GOS can now continue to bring consumers the benefits of fiber in convenient, every day foods.”

Highly effective at low doses, NUTRAFLORA short-chain fructooligosaccharide helps to promote growth of beneficial bacterial in the large intestine. It can be easily incorporated into a wide range of applications such as bars, snacks, cold cereal, dairy, beverages and even confectionery. Produced from non-GMO sucrose (cane sugar), NUTRAFLORA soluble prebiotic fiber is 30 percent as sweet as sugar, helping to enable partial sugar replacement.

HI-MAIZE resistant starch enables flour replacement and caloric reduction in baked goods, nutritional bars, cereals and pastas. It supports balanced energy by reducing the glycemic response to foods and improving carbohydrate metabolism. It is a white fiber that can be seamlessly incorporated into breads, baked goods, snacks and pasta, replacing up to 20 percent of flour. HI-MAIZE 260 resistant starch is the subject of an FDA-authorized qualified health claim for reduced risk of type 2 diabetes (see docket # FDA-2015-Q-2352 for specific claim language).

BIOLIGO GL 5700 galacto-oligosaccharides support immune and digestive health.